L-Ornithine: A Comprehensive Reference
1. Identity
Chemical Names and Classification
L-ornithine, also known as (S)-2,5-diaminopentanoic acid, is a member of the class of compounds known as L-alpha-amino acids. L-ornithine is classified as a non-proteinogenic amino acid due to its absence in protein structures; unlike standard amino acids, it is not incorporated into proteins. The molecular formula of L-ornithine is C₅H₁₂N₂O₂, with a molecular weight of 132.16 g/mol. Structurally, it contains a central α-carbon to which a carboxyl group (–COOH), an amino group (–NH₂), a hydrogen atom, and a distinctive four-carbon side chain are attached. This side chain terminates with an additional amino group (–NH₂), making L-ornithine a dibasic amino acid. L-ornithine is structurally similar to L-lysine; the primary distinction lies in the side chain length, where L-ornithine has one fewer methylene group. This structural difference influences its biochemical roles, particularly in nitrogen metabolism pathways.
Discovery and Nomenclature
The name "ornithine" originates from the Greek word for bird (ornis or ornith-) in reference to its discovery as a benzoate ester in chicken excrement, by Max Jaffe in 1877. It was later recognized as an important biological substance with many remarkable functions.
Natural Food Sources
Ornithine is present in fish and cheese, but also in corbicula (a freshwater clam), which contains considerably more ornithine than other foods. L-ornithine is obtained by humans through certain food sources, such as brackish-water bivalves, scallops, and little-neck clams, as well as mahi-mahi, yellowfin tuna, American red snapper, and green tea. Ornithine is an amino acid found in many foods, including fish, dairy products, and legumes; sardines, salmon, and herring are particularly good sources. As with amino acids in general, ornithine is predominantly found in meat, fish, dairy, and eggs; Western diets typically provide 5 grams per day.
Common Supplemental Forms and Preparations
In addition to dietary uptake, there are many different types of ornithine supplements available. Some common ornithine supplements include a combination of arginine and ornithine, L-ornithine hydrochloride, and ornithine alpha-ketoglutarate (OKG). L-ornithine HCl is the most common supplemental form—stable, water-soluble, and cost-effective. L-ornithine L-aspartate (LOLA) is prescription-grade in many countries (Europe and Japan) and contains the aspartate salt crucial for brain energy metabolism; it is regulated as a drug in some jurisdictions. Ornithine alpha-ketoglutarate (OKG) is a distinct salt form combining ornithine with the Krebs-cycle intermediate alpha-ketoglutarate, used primarily in clinical nutrition. L-ornithine is soluble in water and is a moderately acidic compound.
2. Traditional and Historical Use
L-ornithine, like many other amino acids, was first identified in the early 20th century during the study of amino acid metabolism and the urea cycle. Its role in detoxifying ammonia and supporting liver function was well recognized in biochemistry and clinical nutrition, but its widespread use as a supplement in the context of sports performance and muscle recovery gained traction more recently.
Historically, while ornithine itself was not isolated until the early 20th century, foods and herbal remedies rich in amino acids, including ornithine, have been used in traditional medicine systems to support liver health, boost vitality, and promote healing. Ancient practitioners recognized the restorative power of such nutrients, often recommending broths, fermented foods, and specific herbal mixtures to fortify the body, especially during periods of convalescence or fatigue.
The therapeutic potential of ornithine emerged in the 1960s when researchers developed L-ornithine L-aspartate (LOLA) to treat liver disease. The nootropic and ergogenic applications did not gain real traction until Japanese researchers in the 2000s began exploring L-ornithine's fatigue-modulating properties.
It should be noted that L-ornithine does not figure prominently in the classical herbal pharmacopoeias of ancient Greek, Ayurvedic, or Chinese medicine as an isolated compound—its traditional role was entirely implicit, via dietary protein intake from animal foods.
3. Key Constituents and Mechanisms of Action
Role in the Urea Cycle
Ornithine is a non-proteinogenic α-amino acid that plays an essential role in the urea cycle, to the extent that it is sometimes also called the "ornithine cycle." One of the first steps in the urea cycle involving ornithine is its combination with carbamoyl phosphate to form citrulline. This reaction is catalyzed by the enzyme ornithine transcarbamylase (OTC). The ability of ornithine to regenerate and cyclically participate in the urea cycle makes it indispensable for the detoxification process. Citrulline then undergoes a series of transformations, eventually leading to the production of arginine, which will once again be split into urea and ornithine, thus perpetuating the cycle. In mammals, ammonia is converted into urea for excretion through the urea cycle; about 80% of the nitrogen excretion from amino acids depends on this cycle.
Polyamine Biosynthesis
Ornithine, through the action of ornithine decarboxylase (EC 4.1.1.17), serves as the starting point for the synthesis of polyamines such as putrescine. Ornithine serves as a precursor for polyamine biosynthesis, which involves the synthesis of polyamines such as putrescine, spermidine, and spermine. Ornithine decarboxylase (ODC) catalyzes the conversion of ornithine into putrescine, the first step in polyamine biosynthesis. Putrescine is subsequently converted into spermidine and spermine through enzymatic reactions involving spermidine synthase and spermine synthase. Polyamines play essential roles in cell growth, proliferation, and differentiation and are involved in nucleic acid stabilization, protein synthesis, and cell signaling.
Proline and Collagen Synthesis
Ornithine can be converted into proline through a series of enzymatic reactions in proline biosynthesis. Proline is synthesized from ornithine by the sequential action of ornithine cyclodeaminase and pyrroline-5-carboxylate (P5C) synthetase. Ornithine contributes to the synthesis of proline and glutamate, which are essential for collagen formation and neurotransmitter function, respectively. Increased synthesis of polyamines and proline, in turn, can promote cell proliferation and collagen synthesis—processes that play important roles in wound healing, fibrotic disorders, chronic inflammatory diseases, and infection.
Arginine Biosynthesis and Nitric Oxide
L-ornithine is synthesized from L-arginine and converted into L-citrulline, facilitating nitrogen balance and metabolic efficiency. In mammalian non-hepatic tissues, the primary role of the urea cycle is often the biosynthesis of arginine. Because arginine is the substrate for nitric oxide synthases, ornithine supplementation can indirectly influence nitric oxide-mediated pathways, including vasodilation and immune function.
HPA Axis and Stress Modulation
Orally administered L-ornithine reportedly suppressed corticosterone secretion during restraint stress in mice. Several clinical studies have indicated that L-ornithine oral administration suppresses cortisol increase. Concerning the underlying mechanisms, L-ornithine might exert an inhibitory effect on the HPA axis via the gamma-aminobutyric acid type A receptor (GABAA).
Enzyme Interactions Summary
Ornithine mainly acts as a substrate for the enzymes ornithine transcarbamylase (OTC), ornithine aminotransferase (OAT), and ornithine decarboxylase (ODC), producing citrulline, proline, and polyamines, respectively. The mechanism of action behind the multifaceted roles of ornithine is yet to be completely unraveled.
4. Scientific Evidence by Area of Use
4.1 Fatigue Reduction and Physical Performance
L-ornithine supplementation has been shown to attenuate fatigue in subjects in placebo-controlled studies using a cycle ergometer. The results suggest that L-ornithine may exert an anti-fatigue effect by increasing the efficiency of energy consumption and promoting the excretion of ammonia.
In human studies, L-ornithine administration has been reported to improve physical fatigue and to suppress the elevation of blood ammonia during exercise.
Regarding evidence strength, this area has the most robust human data for L-ornithine as a standalone supplement. However, sample sizes remain small. All human clinical trials of ornithine supplements suffer from very low sample sizes; few human trials have more than 20 participants, so their conclusions must all be taken with a grain of salt. One consequence of the small size of these studies is that no single study could investigate a range of doses. Studies showing no benefit may not have used a large enough dose, and different doses may have different benefits and drawbacks. Some studies supporting claims of benefits to athletic performance were funded and supplied by the manufacturers of ornithine supplements.
It is also important to note that not all studies show benefit: a single dose and 14-day oral intake of tea catechins and ornithine supplementation did not suppress exercise-induced ammonia accumulation or enhance cycling performance. No differences were found in plasma ammonia concentration measured during the whole experimental period. However, subjective fatigue during 60-minute cycling was lower in both acute and chronic ornithine trials than in placebo trials.
4.2 Stress and Mood: Cortisol and Sleep Quality
A randomized, double-blind, placebo-controlled trial published in Nutrition Journal (2014) investigated the effects of L-ornithine on stress markers and sleep quality in healthy workers. This study was a randomised, double-blind and placebo-controlled trial; subjects were randomly allocated to either the L-ornithine group or placebo group. Most previous studies had evaluated the short-term effect of L-ornithine supplementation on healthy volunteers; this trial investigated the long-term effect. Eight weeks was chosen as the study period; subjects ingested either L-ornithine or placebo capsules before going to bed every day for 8 weeks. In a study of 52 stressed but otherwise healthy Japanese adults, 400 mg of ornithine per day reduced fatigue and improved sleep quality.
A separate randomized, double-blind, placebo-controlled parallel-group trial investigated L-ornithine's effects on social-stress-induced fatigue using the Trier Social Stress Test (TSST). 65 participants were randomly assigned to ingest either 1,600 mg of L-ornithine or a placebo for 7 days; on the day of the TSST, participants took test products one hour before the testing. The effects on saliva cortisol and mood states, including fatigue, were evaluated. While L-ornithine did not affect saliva cortisol levels, it significantly improved the fatigue–inertia and anger–hostility scales of the Profile of Mood States on the morning after the TSST in the L-ornithine group compared to the placebo group. The conclusion was that L-ornithine could potentially improve interpersonal social-stress-associated fatigue without involving the HPA axis.
Evidence strength: Preliminary. There are only a small number of randomized controlled trials, all with modest sample sizes and predominantly Japanese populations. The mechanism by which L-ornithine modulates mood or sleep quality is not firmly established in the human literature.
4.3 Hepatic Encephalopathy (via L-Ornithine L-Aspartate)
The most extensively researched clinical application of ornithine-based therapy is hepatic encephalopathy (HE), where it is used primarily as L-ornithine L-aspartate (LOLA), a distinct pharmacological formulation rather than free L-ornithine. L-ornithine-L-aspartate is a chemical that is broken down by the body to increase levels of two amino acids: ornithine and aspartic acid; these amino acids help to reduce levels of the toxic chemical ammonia in the blood.
LOLA has been appraised for the management and treatment of hepatic encephalopathy (HE) in cirrhosis; meta-analyses of randomized controlled trials (RCTs) conducted over the last two decades generally reveal evidence of benefit of LOLA in a range of clinical presentations. Basic research has identified mechanisms responsible for the ammonia-lowering actions of LOLA, including L-ornithine-induced stimulation of urea synthesis by residual periportal hepatocytes and stimulation of ammonia removal via glutamine synthesis in skeletal muscle. Beneficial effects of LOLA have been reported in over 20 randomized controlled clinical trials (RCTs), the findings of the majority of which have been published in peer-reviewed biomedical journals.
A Cochrane systematic review (updated 2025) analyzed 33 RCTs comparing LOLA with placebo or no intervention, and 6 RCTs comparing LOLA with other anti-encephalopathy treatments. Analyses showed L-ornithine L-aspartate might reduce deaths, improve hepatic encephalopathy, and prevent serious side effects compared with placebo or no treatment, but that it had no additional beneficial effects when compared with other medicines used to prevent and treat this condition. The length of treatment varied from three to 35 days in the trials testing the intravenous preparation (average eight days) and from seven to 180 days in those testing the oral preparation (average 30 days). Many studies were unpublished and had not been carefully vetted, and many of the published trials received support from the pharmaceutical industry, which introduces an element of bias. Accordingly, more information is needed before the value of LOLA for preventing and treating hepatic encephalopathy can be determined.
A 2013 meta-analysis of RCTs in patients with cirrhosis reported: hepatic encephalopathy was statistically significantly reduced in patients with both minimal and overt hepatic encephalopathy who received L-ornithine–L-aspartate compared to placebo/no intervention (RR 1.49, 95% CI 1.10 to 2.01; five RCTs).
Evidence strength: Moderate to moderately strong for LOLA (the pharmaceutical formulation). The Cochrane review indicates potential benefit but notes important methodological limitations including industry funding and unpublished studies. LOLA is registered as a pharmaceutical agent in several countries including Germany, India, and Japan for this indication.
4.4 Wound Healing and Tissue Repair (via Ornithine Alpha-Ketoglutarate)
The ornithine alpha-ketoglutarate (OKG) form of ornithine has the most RCT data in wound healing. Ornithine α-ketoglutarate displays anabolic and anti-catabolic properties in situations of stress.
A prospective, randomized double-blind trial in 60 patients with severe burns (20–60% body surface area) evaluated OKG 20 g/day versus isocaloric placebo for 21 days: in the OKG group, nitrogen balance reached positive values at day 5 and stabilized at higher levels versus controls; transthyretin and RBP levels were higher in the OKG group; body weight loss was counteracted in the OKG group (−2.6% vs. −6.3%, p < 0.001); and assessment of wound healing quality showed better performance in the OKG group (p < 0.05).
A separate prospective, double-blind randomized trial in 47 severe burn patients (25–95% total body surface area) tested OKG administered twice daily as a bolus (2 × 10 g) for 3 weeks: wound healing times in patients receiving ornithine α-ketoglutarate or Protil-1 (isonitrogenous control) were 60 ± 7 and 90 ± 12 days, respectively (p < 0.05) for similar grafted surfaces.
A further RCT in 54 burn patients (20–50% total body surface area) tested different OKG doses (10, 20, or 30 g/day): OKG administration significantly improved nitrogen balance and reduced 3-methylhistidine and hydroxyproline urinary elimination, associated with a gradual rise in plasma glutamine over time. Given as a bolus, OKG significantly improved wound healing, assessed clinically by day of last graft (OKG bolus 23.7 ± 2.1 days versus control 39.9 ± 9.9 days; p < 0.05). Data indicated a benefit of 30 g OKG/day administration over 10 g/day based on 3-methylhistidine elimination.
A previous study indicated that ornithine supplementation improved wound breaking strength and collagen deposition in the dorsal skin of mice.
Evidence strength: Moderate for OKG specifically in critical care/burns; the relevant human data use the OKG salt form, not free L-ornithine. Evidence for free L-ornithine supplementation in wound healing in otherwise healthy individuals is limited to preclinical data.
4.5 Growth Hormone Secretion
Amino acid supplements, including L-ornithine, are frequently marketed to bodybuilders and weightlifters with claims of increasing levels of human growth hormone (HGH), muscle mass, and strength. A short, four-day clinical study conducted in 1993 reported that L-ornithine, in combination with L-arginine and L-lysine at 2 g/day each, did not increase HGH levels.
Ornithine acts as a precursor to arginine, which is involved in protein synthesis, and could stimulate the production of growth hormone and insulin-like growth factor 1 (IGF-1). A 2010 study found that arginine and ornithine supplementation increased growth hormone and IGF-1 serum levels after heavy-resistance exercise in strength-trained athletes. However, a dose of 170 mg per kg per day (approximately 11.6 g/day for a 150-pound person) was required to increase growth hormone—above the recommended limit on most supplement labels.
Evidence strength: Weak and inconsistent for growth hormone stimulation at supplemental doses. Only very high doses have demonstrated any effect, and the physiological significance of these transient GH elevations is uncertain.
4.6 Skin Quality and Collagen
Supplementation of L-ornithine reportedly yields wide-ranging health benefits, including growth hormone secretion, improved sleep quality, and enhanced skin strength and wound healing. L-ornithine is a vital component of the urea cycle in the liver, and is reported to have various functions such as promoting wound healing, promoting growth hormone secretion, and hypnotic effects.
In human trials, 400 mg daily improved subjective skin perceptions and elasticity, particularly in fatigued individuals, possibly via collagen support. Following oral administration of L-ornithine in mice, metabolism to L-citrulline was rapid and citrulline concentration remained high.
Evidence strength: Preliminary. Human data are very limited; most mechanistic data come from animal models. Clinically meaningful effects on skin in healthy humans remain unconfirmed.
4.7 Alcohol Metabolism
L-ornithine has been reported to promote alcohol metabolism in the liver, suppress ethanol-induced hepatocellular death, and improve sleep quality after drinking. According to one study, people who take ornithine after consuming alcohol have fewer hangover symptoms; fatigue levels, confusion, and hostility behaviors are reduced the day after. There are still no studies to clarify how ornithine improves hangover symptoms.
Evidence strength: Very preliminary; limited to a small number of human studies and mechanistic animal research.
5. Body Systems and Health Areas
- Hepatic system: Central role in the urea cycle and ammonia detoxification; clinical application as LOLA in hepatic encephalopathy.
- Nitrogen and amino acid metabolism: Ornithine is one of the key reactants in the urea cycle, responsible for 80% of the nitrogen excretion in the body.
- Musculoskeletal and connective tissue: Via polyamine and proline synthesis, supports collagen production and wound healing.
- Central nervous system: L-ornithine might exert an inhibitory effect on the HPA axis via the GABAA receptor. Excess ammonia is also neurotoxic; ornithine's ammonia-clearing role has indirect CNS relevance.
- Endocrine system: Potential modulation of growth hormone and IGF-1 at high doses; possible influence on the cortisol/DHEA-S ratio.
- Integumentary system: Proline and polyamine supply supports skin collagen integrity.
- Metabolic/ocular: Deficiency of ornithine aminotransferase (OAT) leads biochemically to elevated ornithine levels and clinically to gyrate atrophy of the choroid and retina. The progressive chorioretinal degeneration can be slowed down with an arginine-restricted diet, which reduces ornithine levels.
6. Dosage Forms and Doses Reported in Studies
In human research involving ornithine, 5–10 grams are typically used per day, sometimes combined with arginine.
- Fatigue and exercise performance: Studies have used L-ornithine HCl doses in the range of 1–2 g/day in exercise trials. Most studies about athletic performance use doses of 1 gram twice a day.
- Sleep quality and stress markers: Studies about sleep quality and hangover recovery used doses of 400 mg. The randomized social-stress trial used 1,600 mg of L-ornithine for 7 days.
- Growth hormone stimulation: A dose of approximately 170 mg per kg per day was required to increase growth hormone in some studies.
- Hepatic encephalopathy (LOLA, intravenous): In clinical trials, ornithine aspartate injection was administered intravenously at a dose of 10 g/day, once per day.
- Wound healing (OKG form, enteral): In prospective randomized double-blind burn trials, 20 g/day OKG was administered enterally for 21 days. In other trials, ornithine α-ketoglutarate was administered twice a day as a bolus (2 × 10 g) at 9 am and 9 pm for 3 weeks.
- Oral supplemental range (healthy subjects): Ornithine is possibly safe when used at doses up to 500 mg daily for up to 8 weeks, and up to 12 grams daily for 4 weeks.
7. Safety Considerations and Interactions
General Safety Profile
L-ornithine is a nonessential amino acid with many physiological roles. It has been used as a functional food or dietary supplement to ameliorate various maladies, but there is only limited information available about its safety. A systematic review published in Amino Acids (2025) by Yang et al. conducted a comprehensive safety assessment of oral L-ornithine intake in healthy subjects, searching PubMed, Cochrane Library, Ichushi-Web, and EBSCOhost for human clinical trials. The review specifically searched for clinical trials in which L-ornithine was added to ordinary diets in healthy individuals.
Gastrointestinal Effects
Ornithine is possibly safe when used at doses up to 500 mg daily for up to 8 weeks and up to 12 grams daily for 4 weeks, but it might cause stomach or intestine symptoms. Large doses of OKG (>10 g/day given as a single bolus) induce diarrhea, which precludes its use under that mode.
Elevated Ornithine Levels and Ocular Disease
Improper ornithine levels can cause disorders of the urea cycle, such as hyperornithinemia and hyperammonemia, as well as metabolic diseases such as gyrate atrophy and cancer. Deficiency of ornithine-δ-aminotransferase (OAT) leads biochemically to elevated ornithine levels and clinically to gyrate atrophy of the choroid and retina. The progressive chorioretinal degeneration can be slowed down with an arginine-restricted diet, which reduces ornithine levels to <200 µmol/L. Some patients respond to vitamin B6 supplementation.
Pregnancy and Breastfeeding
If there is no evidence of a deficiency, there appears to be no reason to supplement during pregnancy. There is a lack of information regarding taking ornithine while breastfeeding.
Deficiency and Depletion
Since ornithine is produced by the body, a deficiency of this nonessential amino acid is unlikely, though depletion can occur during growth or pregnancy, and after severe trauma or malnutrition.
Drug and Nutrient Interactions
No well-characterized pharmacokinetic drug–ornithine interactions have been identified in the peer-reviewed literature. Because LOLA is used clinically in hepatic encephalopathy alongside other ammonia-lowering agents (lactulose, rifaximin), combination effects are relevant in that therapeutic context: analyses showed LOLA might reduce deaths and improve hepatic encephalopathy compared to placebo or no treatment, but had no additional beneficial effects when compared with other medicines used to prevent and treat this condition. Given ornithine's role as a metabolic intermediate shared with arginine, citrulline, and proline pathways, high-dose supplementation with multiple amino acids in these pathways simultaneously may have additive or competing effects on urea cycle flux, though specific interaction data in humans are limited.
Limitations of the Evidence Base
All human clinical trials of ornithine supplements suffer from very low sample sizes; few human trials have more than 20 participants, and as a result their conclusions must all be taken with a grain of salt. The majority of studies specific to L-ornithine (as opposed to LOLA or OKG) have been conducted in Japanese populations, and generalizability to other populations is uncertain. As of 2018, approximately 170 tonnes of L-ornithine was used globally as a functional food ingredient.
References
Go back